2
RESEARCH METHODOLOGY
36
5
MARKET OVERVIEW
Explore the booming oral proteins market, balancing innovation with cost and regulatory challenges.
53
5.2.1.1
INCREASING BURDEN OF CHRONIC DISEASES
5.2.1.2
ADVANCEMENTS IN DRUG DELIVERY TECHNOLOGIES
5.2.1.3
HIGHER PATIENT COMPLIANCE AND PREFERENCE FOR ORAL ROUTE
5.2.1.4
EXPANDING THERAPEUTIC APPLICATIONS OF ORAL PROTEINS & PEPTIDES
5.2.2.1
HIGH COST OF DRUG DEVELOPMENT
5.2.2.2
CONTRAINDICATION OF ORAL PROTEINS & PEPTIDES
5.2.2.3
STRINGENT REGULATORY APPROVAL PROCESS
5.2.3.1
ROBUST CLINICAL TRIAL PIPELINE FOR ORAL PROTEINS & PEPTIDES
5.2.3.2
GROWING DEMAND FOR PERSONALIZED MEDICINE
5.2.4.1
HURDLES IN FORMULATION AND STABILITY
5.2.4.2
AVAILABILITY OF ALTERNATIVE THERAPIES
5.3.1
ROLE OF RAW MATERIAL VENDORS
5.3.2
ROLE OF PRODUCT PROVIDERS
5.3.4
ROLE OF REGULATORY AUTHORITIES
5.5
SUPPLY CHAIN ANALYSIS
5.6
PORTER’S FIVE FORCES ANALYSIS
5.6.1
THREAT OF NEW ENTRANTS
5.6.2
THREAT OF SUBSTITUTES
5.6.3
BARGAINING POWER OF SUPPLIERS
5.6.4
BARGAINING POWER OF BUYERS
5.6.5
INTENSITY OF COMPETITIVE RIVALRY
5.7
KEY STAKEHOLDERS & BUYING CRITERIA
5.8.1
AVERAGE SELLING PRICE, BY KEY PLAYER
5.8.2
AVERAGE SELLING PRICE, BY COUNTRY & REGION
5.9.1
REGULATORY SCENARIO
5.9.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.11.1.1
TRANSIENT PERMEATION ENHANCERS
5.11.1.2
GASTROINTESTINAL PERMEATION ENHANCEMENT TECHNOLOGY
5.11.1.3
ORAL SCT (OSTORA) TECHNOLOGY
5.11.2
COMPLEMENTARY TECHNOLOGIES
5.11.2.3
TRANSFERRIN-BASED RECOMBINANT FUSION PROTEINS
5.11.3
ADJACENT TECHNOLOGIES
5.11.3.1
ORAMED AND ORASOME
5.11.3.4
OLEOTEC AND SOCTEC
5.13.2
PATENTS APPLIED AND GRANTED, 2014–2025
5.14
REIMBURSEMENT SCENARIO
5.15
KEY CONFERENCES & EVENTS, 2025–2026
5.16
INVESTMENT & FUNDING SCENARIO
5.17
IMPACT OF AI ON ORAL PROTEINS & PEPTIDES MARKET
5.18
IMPACT OF 2025 US TARIFFS—ORAL PROTEINS & PEPTIDES MARKET
5.18.3
PRICE IMPACT ANALYSIS
5.18.4
IMPACT ON COUNTRIES/REGIONS
5.18.5
IMPACT ON MANUFACTURING INDUSTRIES
5.18.6
RECOMMENDATIONS FOR MANUFACTURERS
6
ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 48 Data Tables
90
6.2.1
INCREASED PATIENT COMPLIANCE TO BOOST MARKET GROWTH
6.3.1
NEED FOR EFFECTIVE ANTI-MIGRAINE DRUGS TO SUPPORT ADOPTION
6.4.1
RISING PREVALENCE OF GASTRIC DISORDERS TO SUPPORT GROWTH
6.5.1
FDA APPROVAL TO DRIVE MARKET
6.6.1
INCREASING REGULATORY APPROVALS TO DRIVE PATIENT ACCESS AND ADOPTION
6.7.1
INCREASED PATIENT CONVENIENCE TO SUPPORT GROWTH
7
ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 40 Data Tables
110
7.2
GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS
7.2.1
INCREASING ADOPTION TO SUPPORT GROWTH
7.3
CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONISTS
7.3.1
INCREASING PREVALENCE OF MIGRAINE TO DRIVE ADOPTION
7.4
GUANYLATE CYCLASE-C AGONISTS
7.4.1
RISING PREVALENCE OF IBS AND CIC TO DRIVE MARKET
7.5
GLYCINE-PROLINE-GLUTAMATE
7.5.1
FOCUS ON DEVELOPING GPE-CLASS DRUGS TO SUPPORT GROWTH
7.6
CALCINEURIN-INHIBITOR IMMUNOSUPPRESSANTS
7.6.1
INCREASING NUMBER OF ORGAN TRANSPLANTS TO PROMOTE GROWTH
8
ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 22 Data Tables
127
8.2.1
HIGH ADOPTION AND EASE OF ADMINISTRATION TO SUPPORT GROWTH
8.3.1
RISING DEMAND FOR ORAL BIOLOGICS AND INCREASED PATIENT COMPLIANCE TO DRIVE MARKET
8.4.1
GROWING FOCUS ON IMPROVING BIOAVAILABILITY AND PATIENT CONVENIENCE TO SUPPORT MARKET GROWTH
9
ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 47 Data Tables
137
9.2.1
HIGH EFFICACY TO SUPPORT END-USER ADOPTION
9.3.1
GROWING BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
9.4.1
RISING PREVALENCE OF GASTROINTESTINAL DISORDERS TO SUPPORT SEGMENT GROWTH
9.5.1
GROWING PREVALENCE OF GENETIC DISORDERS TO SUPPORT GROWTH
9.6.1
RISING PREVALENCE OF KIDNEY DISORDERS IN GERIATRIC POPULATION TO PROPEL MARKET
9.7.1
RISING INCIDENCE OF OBESITY TO PROPEL MARKET GROWTH
9.8
OTHER THERAPEUTIC AREAS
10
ORAL PROTEINS & PEPTIDES MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 22 Data Tables
159
10.2.1
RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH
10.3
LONG-TERM CARE FACILITIES
10.3.1
RISING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASES TO SUPPORT GROWTH
10.4
HOSPITALS & SPECIALTY CLINICS
10.4.1
ADOPTION OF ORAL PEPTIDES FOR VARIED INDICATIONS TO DRIVE MARKET
11
ORAL PROTEINS & PEPTIDES MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 17 Countries | 158 Data Tables.
170
11.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2.1
US TO HOLD LARGE SHARES IN NORTH AMERICAN AND GLOBAL MARKETS
11.2.3.1
INCREASING PREVALENCE OF OBESITY AND HEART FAILURE TO SUPPORT MARKET GROWTH
11.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2.1
GERMANY TO HOLD LARGEST SHARE OF EUROPEAN MARKET
11.3.3.1
STRONG FOCUS ON ADVANCEMENT OF LIFE SCIENCES TO SUPPORT MARKET GROWTH
11.3.4.1
GROWING PREVALENCE OF DIABETES AND GOVERNMENT INITIATIVES TO BOOST MARKET GROWTH
11.3.5.1
PRESENCE OF MAJOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DRIVE MARKET
11.3.6.1
INITIATIVES ASSOCIATED WITH GLP-1 DRUGS TO DRIVE MARKET
11.3.7.1
RISING AWARENESS AND FOCUS ON PHARMACEUTICAL R&D TO SUPPORT MARKET GROWTH
11.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2.1
INCREASING R&D EXPENDITURE TO DRIVE MARKET
11.4.3.1
INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET
11.4.4.1
STRONG INITIATIVES TO DEVELOP COST-EFFECTIVE AND PATIENT-FRIENDLY MEDICATIONS TO AID MARKET GROWTH
11.4.5.1
RISING ACCESS TO GLP-1 DRUGS AND GOVERNMENT SUPPORT TO DRIVE MARKET
11.4.6.1
GROWING FOCUS ON DEVELOPMENT OF INNOVATIVE TREATMENT SOLUTIONS TO PROPEL MARKET GROWTH
11.4.7
REST OF ASIA PACIFIC
11.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2.1
BRAZIL TO HOLD LARGEST MARKET SHARE IN LATIN AMERICA
11.5.3.1
GROWING DIABETES AND OBESITY CASES TO DRIVE MARKET
11.5.4
REST OF LATIN AMERICA
11.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST
11.6.2.3
REST OF GCC COUNTRIES
11.6.3
REST OF MIDDLE EAST
11.7.1
LARGE AND GROWING PATIENT POPULATION AND FAVORABLE HEALTHCARE REFORMS TO DRIVE MARKET
11.7.2
MACROECONOMIC OUTLOOK FOR AFRICA
12
COMPETITIVE LANDSCAPE
Decipher market dominance and innovation trends in the oral proteins and peptides competitive landscape.
252
12.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1
OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ORAL PROTEINS & PEPTIDES MARKET
12.3
REVENUE ANALYSIS, 2022–2024
12.4
MARKET SHARE ANALYSIS, 2024
12.5
COMPANY EVALUATION MATRIX
12.5.1
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.5.1.2
EMERGING LEADERS
12.5.1.3
PERVASIVE PLAYERS
12.5.2
COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2024
12.5.2.2
EMERGING LEADERS
12.5.2.3
PERVASIVE PLAYERS
12.5.3
COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.5.3.1
COMPANY FOOTPRINT
12.5.3.2
REGION FOOTPRINT
12.5.3.3
MOLECULE FOOTPRINT
12.5.3.4
FORMULATION FOOTPRINT
12.5.3.5
THERAPEUTIC AREA FOOTPRINT
12.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.6.1
PROGRESSIVE COMPANIES
12.6.2
RESPONSIVE COMPANIES
12.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
12.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
12.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
12.7
VALUATION & FINANCIAL METRICS
12.8
BRAND/PRODUCT COMPARISON
12.9
COMPETITIVE SCENARIO
12.9.4
OTHER DEVELOPMENTS
13
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
276
13.2.1.1
BUSINESS OVERVIEW
13.2.1.2
PRODUCTS OFFERED
13.2.1.3
RECENT DEVELOPMENTS
13.2.4
BAUSCH HEALTH COMPANIES INC.
13.2.5
CHIESI FARMACEUTICI S.P.A.
13.2.6
ACADIA PHARMACEUTICALS INC.
13.2.7
AURINIA PHARMACEUTICALS INC.
13.2.9
JOHNSON & JOHNSON SERVICES, INC.
13.3.2
REGOR THERAPEUTICS GROUP
13.3.3
TERNS PHARMACEUTICALS, INC.
13.3.4
STRUCTURE THERAPEUTICS
13.3.5
VIKING THERAPEUTICS
13.3.6
PROTAGONIST THERAPEUTICS INC.
13.3.8
CARMOT THERAPEUTICS, INC.
13.3.10
SCIWIND BIOSCIENCES CO., LTD.
13.3.11
JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
14.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3
CUSTOMIZATION OPTIONS
TABLE 1
ORAL PROTEINS & PEPTIDES MARKET: IMPACT ANALYSIS
TABLE 2
ORAL PROTEINS & PEPTIDES MARKET: ROLE OF RAW MATERIAL VENDORS
TABLE 3
ORAL PROTEINS & PEPTIDES MARKET: ROLE OF PRODUCT PROVIDERS
TABLE 4
ORAL PROTEINS & PEPTIDES MARKET: ROLE OF END USERS
TABLE 5
ORAL PROTEINS & PEPTIDES MARKET: ROLE OF REGULATORY AUTHORITIES
TABLE 6
ORAL PROTEINS & PEPTIDES MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 7
BUYING CRITERIA FOR ORAL PROTEINS & PEPTIDES, BY END USER
TABLE 8
AVERAGE SELLING PRICE OF ORAL PROTEIN & PEPTIDE PRODUCTS, BY KEY PLAYER, 2024 (USD)
TABLE 9
AVERAGE SELLING PRICE OF ORAL PROTEIN & PEPTIDE PRODUCTS, BY COUNTRY AND REGION, 2024 (USD)
TABLE 10
REGULATORY SCENARIO FOR ORAL PROTEINS & PEPTIDES MARKET
TABLE 11
NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12
EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13
ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14
REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15
ORAL PEPTIDES IN CLINICAL PIPELINE (AS OF JANUARY 2025)
TABLE 16
PATENTS FILED, 2014–2025
TABLE 17
INNOVATIONS AND PATENT REGISTRATIONS, 2023–2024
TABLE 18
ORAL PROTEINS & PEPTIDES MARKET: DETAILED LIST OF CONFERENCES & EVENTS
TABLE 19
US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 20
ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 21
SEMAGLUTIDE MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 22
NORTH AMERICA: SEMAGLUTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 23
EUROPE: SEMAGLUTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 24
ASIA PACIFIC: SEMAGLUTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 25
LATIN AMERICA: SEMAGLUTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 26
MIDDLE EAST: SEMAGLUTIDE MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 27
GCC COUNTRIES: SEMAGLUTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 28
CALCITONIN MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 29
NORTH AMERICA: CALCITONIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 30
EUROPE: CALCITONIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 31
ASIA PACIFIC: CALCITONIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 32
LATIN AMERICA: CALCITONIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 33
MIDDLE EAST: CALCITONIN MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 34
GCC COUNTRIES: CALCITONIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 35
LINACLOTIDE MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 36
NORTH AMERICA: LINACLOTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 37
EUROPE: LINACLOTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 38
ASIA PACIFIC: LINACLOTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 39
LATIN AMERICA: LINACLOTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 40
MIDDLE EAST: LINACLOTIDE MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 41
GCC COUNTRIES: LINACLOTIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 42
TROFINETIDE MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 43
NORTH AMERICA: TROFINETIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 44
EUROPE: TROFINETIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 45
ASIA PACIFIC: TROFINETIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 46
LATIN AMERICA: TROFINETIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 47
MIDDLE EAST: TROFINETIDE MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 48
GCC COUNTRIES: TROFINETIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 49
VOCLOSPORIN MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 50
NORTH AMERICA: VOCLOSPORIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 51
EUROPE: VOCLOSPORIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 52
ASIA PACIFIC: VOCLOSPORIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 53
LATIN AMERICA: VOCLOSPORIN MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 54
PLECANATIDE MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 55
NORTH AMERICA: PLECANATIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 56
EUROPE: PLECANATIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 57
ASIA PACIFIC: PLECANATIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 58
LATIN AMERICA: PLECANATIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 59
MIDDLE EAST: PLECANATIDE MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 60
GCC COUNTRIES: PLECANATIDE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 61
OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 62
NORTH AMERICA: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 63
EUROPE: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 64
ASIA PACIFIC: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 65
LATIN AMERICA: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 66
MIDDLE EAST: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 67
GCC COUNTRIES: OTHER ORAL PROTEIN & PEPTIDE MOLECULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 68
ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 69
GLP-1 RECEPTOR AGONISTS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 70
NORTH AMERICA: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 71
EUROPE: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 72
ASIA PACIFIC: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 73
LATIN AMERICA: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 74
MIDDLE EAST: GLP-1 RECEPTOR AGONISTS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 75
GCC COUNTRIES: GLP-1 RECEPTOR AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 76
CGRP RECEPTOR ANTAGONISTS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 77
NORTH AMERICA: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 78
EUROPE: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 79
ASIA PACIFIC: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 80
LATIN AMERICA: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 81
MIDDLE EAST: CGRP RECEPTOR ANTAGONISTS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 82
GCC COUNTRIES: CGRP RECEPTOR ANTAGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 83
GC-C AGONISTS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 84
NORTH AMERICA: GC-C AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 85
EUROPE: GC-C AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 86
ASIA PACIFIC: GC-C AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 87
LATIN AMERICA: GC-C AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 88
MIDDLE EAST: GC-C AGONISTS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 89
GCC COUNTRIES: GC-C AGONISTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 90
GPE MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 91
NORTH AMERICA: GPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 92
EUROPE: GPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 93
ASIA PACIFIC: GPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 94
LATIN AMERICA: GPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 95
MIDDLE EAST: GPE MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 96
GCC COUNTRIES: GPE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 97
CNI MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 98
NORTH AMERICA: CNI MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 99
EUROPE: CNI MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 100
ASIA PACIFIC: CNI MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 101
OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 102
NORTH AMERICA: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 103
EUROPE: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 104
ASIA PACIFIC: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 105
LATIN AMERICA: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 106
MIDDLE EAST: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 107
GCC COUNTRIES: OTHER ORAL PROTEIN & PEPTIDE DRUG CLASSES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 108
ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 109
ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 110
NORTH AMERICA: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 111
EUROPE: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 112
ASIA PACIFIC: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 113
LATIN AMERICA: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 114
MIDDLE EAST: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 115
GCC COUNTRIES: ORAL PROTEIN & PEPTIDE TABLETS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 116
ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 117
NORTH AMERICA: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 118
EUROPE: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 119
ASIA PACIFIC: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 120
LATIN AMERICA: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 121
MIDDLE EAST: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 122
GCC COUNTRIES: ORAL PROTEIN & PEPTIDE CAPSULES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 123
ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 124
NORTH AMERICA: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 125
EUROPE: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 126
ASIA PACIFIC: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 127
LATIN AMERICA: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 128
MIDDLE EAST: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 129
GCC COUNTRIES: ORAL PROTEIN & PEPTIDE SOLUTIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 130
ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 131
ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY REGION, 2023–2030 (USD MILLION)
TABLE 132
NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 133
EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 134
ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 135
LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 136
MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY REGION, 2023–2030 (USD MILLION)
TABLE 137
GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR DIABETES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 138
ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 139
NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 140
EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 141
ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 142
LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 143
MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 144
GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR CNS DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 145
ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY REGION, 2023–2030 (USD MILLION)
TABLE 146
NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 147
EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 148
ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 149
LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 150
MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY REGION, 2023–2030 (USD MILLION)
TABLE 151
GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 152
ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 153
NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 154
EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 155
ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 156
LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 157
MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 158
GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 159
ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY REGION, 2023–2030 (USD MILLION)
TABLE 160
NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 161
EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 162
ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR NEPHROLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 163
ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY REGION, 2023–2030 (USD MILLION)
TABLE 164
NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 165
EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 166
ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 167
LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 168
MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY REGION, 2023–2030 (USD MILLION)
TABLE 169
GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR OBESITY & OVERWEIGHT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 170
ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION)
TABLE 171
NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 172
EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 173
ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 174
LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 175
MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION)
TABLE 176
GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 177
ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 178
ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY REGION, 2023–2030 (USD MILLION)
TABLE 179
NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 180
EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 181
ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 182
LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 183
MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY REGION, 2023–2030 (USD MILLION)
TABLE 184
GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 185
ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 186
NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 187
EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 188
ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 189
LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 190
MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 191
GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 192
ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2023–2030 (USD MILLION)
TABLE 193
NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 194
EUROPE: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 195
ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 196
LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 197
MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2023–2030 (USD MILLION)
TABLE 198
GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 199
ORAL PROTEINS & PEPTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 200
NORTH AMERICA: KEY MACROINDICATORS
TABLE 201
NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 202
NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 203
NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 204
NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 205
NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 206
NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 207
US: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 208
US: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 209
US: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 210
US: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 211
US: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 212
CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 213
CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 214
CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 215
CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 216
CANADA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 217
EUROPE: KEY MACROINDICATORS
TABLE 218
EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 219
EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 220
EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 221
EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 222
EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 223
EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 224
GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 225
GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 226
GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 227
GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 228
GERMANY: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 229
UK: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 230
UK: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 231
UK: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 232
UK: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 233
UK: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 234
FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 235
FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 236
FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 237
FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 238
FRANCE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 239
ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 240
ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 241
ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 242
ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 243
ITALY: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 244
SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 245
SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 246
SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 247
SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 248
SPAIN: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 249
NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 250
NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 251
NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 252
NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 253
NETHERLANDS: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 254
REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 255
REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 256
REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 257
REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 258
REST OF EUROPE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 259
ASIA PACIFIC: KEY MACROINDICATORS
TABLE 260
ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 261
ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 262
ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 263
ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 264
ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 265
ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 266
CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 267
CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 268
CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 269
CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 270
CHINA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 271
JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 272
JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 273
JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 274
JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 275
JAPAN: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 276
INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 277
INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 278
INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 279
INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 280
INDIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 281
AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 282
AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 283
AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 284
AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 285
AUSTRALIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 286
SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 287
SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 288
SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 289
SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 290
SOUTH KOREA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 291
REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 292
REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 293
REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 294
REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 295
REST OF ASIA PACIFIC: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 296
LATIN AMERICA: KEY MACROINDICATORS
TABLE 297
LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 298
LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 299
LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 300
LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 301
LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 302
LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 303
BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 304
BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 305
BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 306
BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 307
BRAZIL: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 308
MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 309
MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 310
MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 311
MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 312
MEXICO: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 313
REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 314
REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 315
REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 316
REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 317
REST OF LATIN AMERICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 318
MIDDLE EAST: KEY MACROINDICATORS
TABLE 319
MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 320
MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 321
MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 322
MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 323
MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 324
MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 325
GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 326
GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 327
GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 328
GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 329
GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 330
GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 331
SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 332
SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 333
SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 334
SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 335
SAUDI ARABIA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 336
UAE: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 337
UAE: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 338
UAE: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 339
UAE: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 340
UAE: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 341
REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 342
REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 343
REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 344
REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 345
REST OF GCC COUNTRIES: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 346
REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 347
REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 348
REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 349
REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 350
REST OF MIDDLE EAST: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 351
AFRICA: KEY MACROINDICATORS
TABLE 352
AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
TABLE 353
AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS, 2023–2030 (USD MILLION)
TABLE 354
AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
TABLE 355
AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
TABLE 356
AFRICA: ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 357
OVERVIEW OF STRATEGIES DEPLOYED BY KEY ORAL PROTEIN & PEPTIDE MANUFACTURERS
TABLE 358
ORAL PROTEINS & PEPTIDES MARKET: DEGREE OF COMPETITION
TABLE 359
ORAL PROTEINS & PEPTIDES MARKET: REGION FOOTPRINT (KEY PLAYERS)
TABLE 360
ORAL PROTEINS & PEPTIDES MARKET: REGION FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
TABLE 361
ORAL PROTEINS & PEPTIDES MARKET: MOLECULE FOOTPRINT (KEY PLAYERS)
TABLE 362
ORAL PROTEINS & PEPTIDES MARKET: FORMULATION FOOTPRINT (KEY PLAYERS)
TABLE 363
ORAL PROTEINS & PEPTIDES MARKET: THERAPEUTIC AREA FOOTPRINT (KEY PLAYERS)
TABLE 364
ORAL PROTEINS & PEPTIDES MARKET: THERAPEUTIC AREA FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
TABLE 365
ORAL PROTEINS & PEPTIDES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 366
ORAL PROTEINS & PEPTIDES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 367
ORAL PROTEINS & PEPTIDES MARKET: PRODUCT APPROVALS, JANUARY 2021–JANUARY 2025
TABLE 368
ORAL PROTEINS & PEPTIDES MARKET: DEALS, JANUARY 2021–JANUARY 2025
TABLE 369
ORAL PROTEINS & PEPTIDES MARKET: EXPANSIONS, JANUARY 2021– JANUARY 2025
TABLE 370
ORAL PROTEINS & PEPTIDES MARKET: OTHER DEVELOPMENTS, JANUARY 2021– JANUARY 2025
TABLE 371
NOVO NORDISK A/S: COMPANY OVERVIEW
TABLE 372
NOVO NORDISK A/S: PRODUCTS OFFERED
TABLE 373
NOVO NORDISK A/S: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2025
TABLE 374
NOVO NORDISK A/S: DEALS, JANUARY 2021–MARCH 2025
TABLE 375
NOVO NORDISK: EXPANSIONS, JANUARY 2021–MARCH 2025
TABLE 376
NOVO NORDISK: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2025
TABLE 377
ABBVIE INC.: COMPANY OVERVIEW
TABLE 378
ABBVIE INC.: PRODUCTS OFFERED
TABLE 379
ABBVIE INC.: PRODUCT APPROVALS, JANUARY 2021–JANUARY 2025
TABLE 380
ABBVIE INC.: DEALS, JANUARY 2021–JANUARY 2025
TABLE 381
PFIZER INC.: COMPANY OVERVIEW
TABLE 382
PFIZER INC.: PRODUCT PIPELINE
TABLE 383
PFIZER INC.: PRODUCT APPROVALS, JANUARY 2021–MARCH 2025
TABLE 384
PFIZER INC.: DEALS, JANUARY 2021–MARCH 2025
TABLE 385
PFIZER INC.: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2025
TABLE 386
BAUSCH HEALTH COMPANIES: COMPANY OVERVIEW
TABLE 387
BAUSCH HEALTH COMPANIES: PRODUCTS OFFERED
TABLE 388
BAUSCH HEALTH COMPANIES: PRODUCT APPROVALS, JANUARY 2021–JANUARY 2025
TABLE 389
CHIESI FARMACEUTICI S.P.A.: COMPANY OVERVIEW
TABLE 390
CHIESI FARMACEUTICI S.P.A.: PRODUCTS OFFERED
TABLE 391
CHIESI FARMACEUTICI S.P.A.: DEALS, JANUARY 2021–JANUARY 2025
TABLE 392
ACADIA PHARMACEUTICALS INC.: COMPANY OVERVIEW
TABLE 393
ACADIA PHARMACEUTICALS INC.: PRODUCTS OFFERED
TABLE 394
ACADIA PHARMACEUTICALS INC.: PRODUCT APPROVALS, JANUARY 2021–JANUARY 2025
TABLE 395
AURINIA PHARMACEUTICALS INC.: COMPANY OVERVIEW
TABLE 396
AURINIA PHARMACEUTICALS INC.: PRODUCTS OFFERED
TABLE 397
AURINIA PHARMACEUTICALS INC.: PRODUCT APPROVALS, JANUARY 2021–JANUARY 2025
TABLE 398
MERCK & CO., INC.: COMPANY OVERVIEW
TABLE 399
MERCK & CO., INC.: PRODUCT PIPELINE
TABLE 400
MERCK & CO., INC.: DEALS, JANUARY 2021–JANUARY 2025
TABLE 401
MERCK & CO., INC.: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025
TABLE 402
JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
TABLE 403
JOHNSON & JOHNSON SERVICES, INC.: PRODUCT PIPELINE
TABLE 404
JOHNSON & JOHNSON SERVICES, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2025
TABLE 405
SWK HOLDINGS: COMPANY OVERVIEW
TABLE 406
SWK HOLDINGS: PRODUCT PIPELINE
TABLE 407
SWK HOLDINGS: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025
TABLE 408
R-PHARM JSC: COMPANY OVERVIEW
TABLE 409
R-PHARM JSC: PRODUCTS IN PIPELINE
TABLE 410
ENTERA BIO: COMPANY OVERVIEW
TABLE 411
ENTERA BIO: PRODUCT PIPELINE
TABLE 412
ENTERA BIO: DEALS, JANUARY 2021–JANUARY 2025
TABLE 413
ENTERA BIO: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025
TABLE 414
PROXIMA CONCEPTS: COMPANY OVERVIEW
TABLE 415
PROXIMA CONCEPTS: PRODUCTS IN PIPELINE
FIGURE 1
BREAKDOWN OF PRIMARIES: SUPPLY AND DEMAND-SIDE PARTICIPANTS
FIGURE 2
MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2024
FIGURE 3
MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2024
FIGURE 4
MARKET VALIDATION FROM PRIMARY EXPERTS
FIGURE 5
MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 6
CAGR PROJECTIONS: ORAL PROTEINS & PEPTIDES MARKET, 2025–2030
FIGURE 7
IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN ORAL PROTEINS & PEPTIDES MARKET
FIGURE 8
DATA TRIANGULATION METHODOLOGY
FIGURE 9
ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE, 2025 VS. 2030 (USD MILLION)
FIGURE 10
ORAL PROTEINS & PEPTIDES MARKET SHARE, BY DRUG CLASS, 2025 VS. 2030 (USD MILLION)
FIGURE 11
ORAL PROTEINS & PEPTIDES MARKET SHARE, BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION)
FIGURE 12
ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION, 2025 VS. 2030 (USD MILLION)
FIGURE 13
ORAL PROTEINS & PEPTIDES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 14
GEOGRAPHICAL SNAPSHOT OF ORAL PROTEINS & PEPTIDES MARKET
FIGURE 15
INCREASING APPROVALS OF ORAL PROTEIN & PEPTIDE DRUGS TO DRIVE MARKET GROWTH
FIGURE 16
TABLETS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2024
FIGURE 17
DIABETES ACCOUNTED FOR LARGEST MARKET SHARE IN 2024
FIGURE 18
HOME CARE SETTINGS TO DOMINATE MARKET TILL 2030
FIGURE 19
UK TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 20
ORAL PROTEINS & PEPTIDES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 21
ORAL PROTEINS & PEPTIDES MARKET: ECOSYSTEM ANALYSIS
FIGURE 22
ORAL PROTEINS & PEPTIDES MARKET: VALUE CHAIN ANALYSIS
FIGURE 23
ORAL PROTEINS & PEPTIDES MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 24
ORAL PROTEINS & PEPTIDES MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 25
INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF ORAL PROTEINS & PEPTIDES
FIGURE 26
KEY BUYING CRITERIA FOR END USERS
FIGURE 27
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 28
PATENT ANALYSIS OF ORAL PROTEINS & PEPTIDE MARKET, JANUARY 2014–JANUARY 2025
FIGURE 29
ORAL PROTEINS & PEPTIDES MARKET: INVESTMENT & FUNDING SCENARIO
FIGURE 30
NORTH AMERICA ORAL PROTEINS & PEPTIDES MARKET SNAPSHOT
FIGURE 31
EUROPE: ORAL PROTEINS & PEPTIDES MARKET SNAPSHOT
FIGURE 32
REVENUE ANALYSIS OF KEY PLAYERS IN ORAL PROTEINS & PEPTIDES MARKET, 2022–2024 (USD MILLION)
FIGURE 33
MARKET SHARE ANALYSIS OF KEY PLAYERS IN ORAL PROTEINS & PEPTIDES (2024)
FIGURE 34
ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 35
ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX (PLAYERS WITH PRODUCTS IN PIPELINE), 2024
FIGURE 36
ORAL PROTEINS & PEPTIDES MARKET: COMPANY FOOTPRINT (KEY PLAYERS)
FIGURE 37
ORAL PROTEINS & PEPTIDES MARKET: COMPANY FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
FIGURE 38
ORAL PROTEINS & PEPTIDES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 39
EV/EBITDA OF KEY VENDORS
FIGURE 40
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 41
ORAL PROTEINS & PEPTIDES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 42
NOVO NORDISK A/S: COMPANY SNAPSHOT (2024)
FIGURE 43
ABBVIE INC.: COMPANY SNAPSHOT (2024)
FIGURE 44
PFIZER INC.: COMPANY SNAPSHOT (2024)
FIGURE 45
BAUSCH HEALTH COMPANIES: COMPANY SNAPSHOT (2024)
FIGURE 46
CHIESI FARMACEUTICI S.P.A.: COMPANY SNAPSHOT (2024)
FIGURE 47
ACADIA PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2024)
FIGURE 48
AURINIA PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2024)
FIGURE 49
MERCK & CO., INC.: COMPANY SNAPSHOT (2024)
FIGURE 50
JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2024)
FIGURE 51
SWK HOLDINGS: COMPANY SNAPSHOT (2024)
Growth opportunities and latent adjacency in Oral Proteins & Peptides Market